IMS Annual Meeting - International Myeloma Society Annual Meeting

A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.

Ramantamig trispecific shows deep, durable myeloma responses, with tocilizumab easing CRS and enabling safer outpatient dosing.

MRD-guided stopping in multiple myeloma shows many patients stay disease-free for 4 years.

TecDara shows strong myeloma control, but early infection risk demands vigilant prophylaxis; safety improves after six months, supporting second-line use.

Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.

A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.

IRAKLIA data show that isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion rates.

New BCMA bispecific shows durable myeloma responses with low severe CRS/ICANS, fewer infections, and convenient outpatient dosing in TRAVINO.

Gut microbiome disruption from antianaerobic antibiotics weakens CAR T-cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.

Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.

Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.

For as long as practicing oncology pharmacists have been in the field, multiple myeloma has carried a standard caveat: treatable, not curable. Now that is changing.

Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.

A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.

Expert shares notable findings presented at the 2025 IMS Annual Meeting.

In this video, experts who attended the 2025 International Myeloma Society (IMS) Annual Meeting highlighted topics of interest as well as pivotal data.

Cevostamab shows promise as a post-CAR T therapy for relapsed/refractory multiple myeloma, enhancing MRD-negative responses and improving patient outcomes.

Etentamig shows promise in managing infections for relapsed/refractory multiple myeloma.

Patients with newly diagnosed transplant-eligible multiple myeloma (NDTE-MM) had high rates of complete response and minimal residual disease–negativity.

Anitocabtagene autoleucel shows impressive efficacy and safety in treating relapsed/refractory multiple myeloma, achieving a 97% overall response rate.

Xavier Leleu, MD, PhD, shares how OBI technology reduces preparation time and manual pushes for pharmacists.

Expert shares the evolving role of pharmacy in patient care, emphasizing treatment accessibility and monitoring.

In a dose-escalation portion of LINKER-MM4, linvoseltamab monotherapy demonstrated a high overall response rate (ORR) and minimal residual disease (MRD) negativity in both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

New IMWG/IMS guidelines enhance risk assessment for multiple myeloma, revealing daratumumab's impact on patient outcomes in real-world settings.

New research links rapid CAR T-cell expansion to delayed neurotoxicity in patients with multiple myeloma.

Claudio Cerchione, MD, PhD, discusses the benefits of anti-CD38 quadruplet regimens for older patients with multiple myeloma.

Expert shares the promising potential of linvoseltamab in treating high-risk smoldering multiple myeloma.

Expert shares the latest advancements in CAR T therapy and novel treatments for myeloma, addressing access challenges and promising new options.

Elranatamab enhances MRD negativity in relapsed/refractory multiple myeloma post idecabtagene vicleucel, promising improved treatment outcomes.

Expert discusses groundbreaking studies on the on-body injector for isatuximab, highlighting its efficacy, safety, and patient convenience.